Oncolytic viruses in lung cancer treatment: a review article

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J. Clin. Invest. 117(10), 2740–2750 (2007).
  Medline CASGoogle Scholar
• 2. Surveillance, Epidemiology, and End Results . Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html#content
  Google Scholar
• 3. Gasperino J. Gender is a risk factor for lung cancer. Med. Hypotheses 76(3), 328–331 (2011).
  MedlineGoogle Scholar
• 4. Lahiri A, Maji A, Potdar PD et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer 22(1), 40 (2023).
  MedlineGoogle Scholar
• 5. Nwagbara UI, Ginindza TG, Hlongwana KW. Lung cancer awareness and palliative care interventions implemented in low-and middle-income countries: a scoping review. BMC Public Health 20(1), 1466 (2020).
  MedlineGoogle Scholar
• 6. Abolfathi H, Sheikhpour M, Shahraeini SS, Khatami S, Nojoumi SA. Studies in lung cancer cytokine proteomics: a review. Expert Rev. Proteomics 18(1), 49–64 (2021).
  Medline CASGoogle Scholar
• 7. Sheikhpour M, Golbabaie A, Kasaeian A. Carbon nanotubes: a review of novel strategies for cancer diagnosis and treatment. Mater Sci. Eng. C Mater. Biol. Appl. 76, 1289–1304 (2017).
  Medline CASGoogle Scholar
• 8. Yang L, Wang Z. Natural products, alone or in combination with FDA-approved drugs, to treat COVID-19 and lung cancer. Biomedicine 9(6), 689 (2021).
  CASGoogle Scholar
• 9. Zhang H, Xie R, Ai-Furas H et al. Design, synthesis, and biological evaluation of novel EGFR protacs targeting del19/T790M/C797S mutation. ACS Med. Chem. Lett. 13(2), 278–283 (2022).
  Medline CASGoogle Scholar
• 10. Wang Z, Yang L, Li Y et al. An activatable, carrier-free, triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer high-permeable targeted chemotherapy. New J. Chem. 46, 17673–17677 (2022).
  CASGoogle Scholar
• 11. Jin J, Zhu YL, Sun F et al. Synergistic antitumor effect of the combination of a dual cancer-specific oncolytic adenovirus and cisplatin on lung cancer cells. Oncol. Lett. 16(5), 6275–6282 (2018).
  Medline CASGoogle Scholar
• 12. Hoyos V, Del Bufalo F, Yagyu S et al. Mesenchymal stromal cells for linked delivery of oncolytic and apoptotic adenoviruses to non-small-cell lung cancers. Mol. Ther. 23(9), 1497–1506 (2015).
  Medline CASGoogle Scholar
• 13. Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe 15(3), 260–265 (2014).
  Medline CASGoogle Scholar
• 14. Chaurasiya S, Chen NG, Warner SG. Oncolytic virotherapy versus cancer stem cells: a review of approaches and mechanisms. Cancers 10(4), 124 (2018).
  MedlineGoogle Scholar
• 15. Liu TC, Thorne SH, Kirn DH. Oncolytic adenoviruses for cancer gene therapy. Methods Mol. Biol. 433, 243–258 (2008).
  Medline CASGoogle Scholar
• 16. Leber MF, Neault S, Jirovec E et al. Engineering and combining oncolytic measles virus for cancer therapy. Cytokine Growth Factor Rev. 56, 39–48 (2020).
  Medline CASGoogle Scholar
• 17. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 17(10), 1667–1676 (2009).
  Medline CASGoogle Scholar
• 18. Polack FP, Lee SH, Permar S et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6(7), 776–781 (2000).
  Medline CASGoogle Scholar
• 19. Pidelaserra-Martí G, Engeland CE. Mechanisms of measles virus oncolytic immunotherapy. Cytokine Growth Factor Rev. 56, 28–38 (2020).
  Medline CASGoogle Scholar
• 20. Ekeke CN, Russell KL, Joubert K et al. Fighting fire with fire: oncolytic virotherapy for thoracic malignancies. Ann. Surg. Oncol. 28(5), 2715–2727 (2021). • Investigates oncolytic virotherapy effectively.
  MedlineGoogle Scholar
• 21. Jiang Y-Q, Zhang Z, Cai H-R, Zhou H. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines. Int. J. Clin. Exp. Pathol. 8(11), 13785 (2015).
  Medline CASGoogle Scholar
• 22. Lynch JP 3rd, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin. Respir. Crit. Care Med. 37(4), 586–602 (2016).
  MedlineGoogle Scholar
• 23. Fernández-Ulibarri I, Hammer K, Arndt MAE et al. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int. J. Cancer 136(9), 2228–2240 (2015).
  Medline CASGoogle Scholar
• 24. Lei W, Liu HB, Wang SB et al. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model. Acta Pharmacol. Sin. 34(4), 531–540 (2013).
  Medline CASGoogle Scholar
• 25. Sun DF, Tian H, Liu XX, Zhang B, Zhang Y, Sun QF. Inhibitory effects of ODC and AdoMetDC bi-antisense virus on the growth and invasion of lung cancer cell A-549. Zhonghua Wai Ke Za Zhi 46(1), 61–64 (2008).
  MedlineGoogle Scholar
• 26. Sipo I, Hurtado Picó A, Wang X et al. An improved Tet-On regulatable FasL–adenovirus vector system for lung cancer therapy. J. Mol. Med. 84(3), 215–225 (2006).
  Medline CASGoogle Scholar
• 27. Yoon AR, Kasala D, Li Y et al. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. J. Control. Rel. 231, 2–16 (2016).
  Medline CASGoogle Scholar
• 28. Davis JJ, Wang L, Dong F et al. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther. 13(7), 720–723 (2006).
  Medline CASGoogle Scholar
• 29. Gomez-Gutierrez JG, Nitz J, Sharma R et al. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo. Virology 487, 249–259 (2016).
  Medline CASGoogle Scholar
• 30. Gomez-Gutierrez JG, Rao XM, Zhou HS, McMasters KM. Enhanced cancer cell killing by truncated E2F-1 used in combination with oncolytic adenovirus. Virology 433(2), 538–547 (2012).
  Medline CASGoogle Scholar
• 31. Zhang JF, Wei F, Wang HP et al. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J. Exp. Clin. Cancer Res. 29(1), 52 (2010).
  MedlineGoogle Scholar
• 32. Li S, Qi Z, Li H et al. Conditionally replicating oncolytic adenoviral vector expressing arresten and tumor necrosis factor-related apoptosis-inducing ligand experimentally suppresses lung carcinoma progression. Mol. Med. Rep. 12(2), 2068–2074 (2015).
  Medline CASGoogle Scholar
• 33. Wang D, Shi L. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Appl. Biochem. Biotechnol. 157(1), 1–9 (2009).
  Medline CASGoogle Scholar
• 34. Yang Y, Xu H, Huang W et al. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J. Cell. Mol. Med. 19(5), 915–923 (2015).
  Medline CASGoogle Scholar
• 35. Yan X, Wang L, Zhang R et al. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using adenovirus-mediated gene therapy. Oncoimmunology 7(1), e1376156 (2017).
  MedlineGoogle Scholar
• 36. Zhang R, Zhang X, Ma B et al. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer. Cancer Gene Ther. 23(6), 168–177 (2016).
  Medline CASGoogle Scholar
• 37. Xie H, Hu J, Pan H, Lou Y, Lv P, Chen Y. Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells. BMB Rep. 47(2), 104–109 (2014).
  MedlineGoogle Scholar
• 38. Lei J, Li Q-H, Yang J-L et al. The antitumor effects of oncolytic adenovirus H101 against lung cancer. Int. J. Oncol. 47(2), 555–562 (2015).
  Medline CASGoogle Scholar
• 39. Wang Y, Ma L, Wang S et al. Assessment of CAR- or CD46-dependent adenoviral vector-mediated TRAIL gene therapy in clinical adenocarcinoma lung cancer cells. Oncology 77(6), 366–377 (2009).
  Medline CASGoogle Scholar
• 40. Kanno T, Gotoh A, Nakano T, Tagawa M, Nishizaki T. Beneficial oncolytic effect of fiber-substituted conditionally replicating adenovirus on human lung cancer. Anticancer Res. 32(11), 4891–4895 (2012).
  Medline CASGoogle Scholar
• 41. Kanerva A, Nokisalmi P, Diaconu I et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res. 19(10), 2734–2744 (2013).
  Medline CASGoogle Scholar
• 42. Lee C-T, Park M-Y, Kang Y, Yoon H-I, Lee J-H. P3-029: genetic immunotherapy using conditionally replicating adenovirus and cytokine adenovirus in lung cancer. J. Thorac. Oncol. 2(8), S619 (2007).
  MedlineGoogle Scholar
• 43. Sheikhpour M, Arabi M, Kasaeian A, Rokn Rabei A, Taherian Z. Role of nanofluids in drug delivery and biomedical technology: methods and applications. Nanotechnol. Sci. Appl. 13, 47–59 (2020).
  Medline CASGoogle Scholar
• 44. Garofalo M, Villa A, Rizzi N, Kuryk L, Mazzaferro V, Ciana P. Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies. Viruses 10(10), 558 (2018).
  MedlineGoogle Scholar
• 45. Kamazani FM, Sotoodehnejad Nematalahi F, Siadat SD, Pornour M, Sheikhpour M. A success targeted nano delivery to lung cancer cells with multi-walled carbon nanotubes conjugated to bromocriptine. Sci. Rep. 11(1), 24419 (2021). • Nano delivery can be a good idea to transfer viruses to the tumor.
  Medline CASGoogle Scholar
• 46. Fukazawa T, Maeda Y, Matsuoka J et al. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant–adenovirus-mediated gene transfer. Anticancer Res. 30(12), 4925–4936 (2010).
  Medline CASGoogle Scholar
• 47. Hakkarainen T, Sarkioja M, Lehenkari P et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther. 18(7), 627–641 (2007).
  Medline CASGoogle Scholar
• 48. Kloos A, Woller N, Gurlevik E et al. PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol. Res. 3(7), 751–763 (2015).
  Medline CASGoogle Scholar
• 49. Li BH, Liu XR, Fan JK et al. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J. Gene Med. 8(10), 1232–1242 (2006).
  Medline CASGoogle Scholar
• 50. Zhu ZB, Makhija SK, Lu B et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J. Thorac. Oncol. 1(7), 701–711 (2006).
  MedlineGoogle Scholar
• 51. Xiaojiang T, Jinsong Z, Jiansheng W, Chengen P, Guangxiao Y, Quanying W. Adeno-associated virus harboring fusion gene NT4-ant-shepherdin induce cell death in human lung cancer cells. Cancer Invest. 28(5), 465–471 (2010).
  MedlineGoogle Scholar
• 52. Wu J-Q, Zhao W-H, Li Y, Zhu B, Yin K-S. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy. Virology 368(2), 309–316 (2007).
  Medline CASGoogle Scholar
• 53. Cai KX, Tse LY, Leung C, Tam PK, Xu R, Sham MH. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin. Cancer Res. 14(3), 939–949 (2008).
  Medline CASGoogle Scholar
• 54. Tseng SJ, Kempson IM, Liao Z-X, Ho Y-C, Yang P-C. An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy. Nano Today 46, 101582 (2022).
  CASGoogle Scholar
• 55. Zaki K, Agundez L, Sanchez B et al. Adeno-associated virus gene therapy for the treatment of epidermal growth factor receptor positive (EGFR) lung cancer. Hum. Gene Ther. 27(7), A18–A19 (2016).
  Google Scholar
• 56. Ajam-Hosseini M, Akhoondi F, Doroudian M. Nano based-oncolytic viruses for cancer therapy. Crit. Rev. Oncol. Hematol. 185, 103980 (2023).
  MedlineGoogle Scholar
• 57. Doroudian M, Zanganeh S, Abbasgholinejad E, Donnelly SC. Nanomedicine in lung cancer immunotherapy. Front. Bioeng. Biotechnol. 11(17), 1144653 (2023).
  MedlineGoogle Scholar
• 58. Doroudian M, Azhdari MH, Goodarzi N, O’Sullivan D, Donnelly SC. Smart nanotherapeutics and lung cancer. Pharmaceutics 13(11), 1972 (2021).
  Medline CASGoogle Scholar
• 59. Hassan M, Braam SR, Kruyt FAE. Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells. Cancer Gene Ther. 13(12), 1105–1114 (2006).
  MedlineGoogle Scholar
• 60. Garofalo M, Saari H, Somersalo P et al. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J. Control. Rel. 283, 223–234 (2018).
  Medline CASGoogle Scholar
• 61. Bai RZ, Wu Y, Liu Q et al. Suppression of lung cancer in murine model: treated by combination of recombinant human endostsatin adenovirus with low-dose cisplatin. J. Exp. Clin. Cancer Res. 28(1), 31 (2009).
  MedlineGoogle Scholar
• 62. Liu D, Kojima T, Ouchi M et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol. Cancer Ther. 8(4), 980–987 (2009).
  Medline CASGoogle Scholar
• 63. Rohr UP, Wulf MA, Stahn S et al. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector. Cancer Gene Ther. 10(12), 898–906 (2003).
  Medline CASGoogle Scholar
• 64. Zhong SY, Yu DB, Wang YG, Qiu SB, Wu SJ, Liu XY. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol. 49(1), 91–99 (2010).
  Medline CASGoogle Scholar
• 65. Song G, Shang C, Sun L et al. Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo. Invest. New Drugs 40(2), 274–289 (2022). •• Engineered Ad-VT chemotherapy-resistant lung cancer which caused more autophagy.
  Medline CASGoogle Scholar
• 66. Li T, Fang J, Chu J et al. In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide. J. Cancer Res. Clin. Oncol. 148(5), 1073–1085 (2022).
  Medline CASGoogle Scholar
• 67. Wunder T, Schmid K, Wicklein D et al. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection. Cancer Gene Ther. 20(1), 25–32 (2013).
  Medline CASGoogle Scholar
• 68. Sakhawat A, Liu Y, Ma L et al. Upregulation of coxsackie adenovirus receptor sensitizes cisplatin-resistant lung cancer cells to CRAd-induced inhibition. J. Cancer 8(8), 1425–1432 (2017).
  MedlineGoogle Scholar
• 69. Tango Y, Taki M, Shirakiya Y et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci. 95(5), 459–463 (2004).
  Medline CASGoogle Scholar
• 70. Kim D, Park M, Lee C et al. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther. 18(7), 467–477 (2011).
  Medline CASGoogle Scholar
• 71. Watanabe T, Hioki M, Fujiwara T et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp. Cell Res. 312(3), 256–265 (2006).
  Medline CASGoogle Scholar
• 72. Sarkioja M, Kanerva A, Salo J et al. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 107(7), 1578–1588 (2006).
  MedlineGoogle Scholar
• 73. Liu H, Luo H. Development of group B coxsackievirus as an oncolytic virus: opportunities and challenges. Viruses 13(6),1082 (2021).
  Medline CASGoogle Scholar
• 74. Deng H, Liu H, de Silva T et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol. Ther. Oncolytics 14, 266–278 (2019).
  Medline CASGoogle Scholar
• 75. Liu HT, Xue YC, Deng HY et al. MicroRNA modification of coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer. Mol. Ther. Oncolytics 16, 207–218 (2020).
  Medline CASGoogle Scholar
• 76. Hoballa MH, Soltani BM, Mowla SJ, Sheikhpour M, Kay M. Identification of a novel intergenic miRNA located between the human DDC and COBL genes with a potential function in cell cycle arrest. Mol. Cell. Biochem. 444(1–2), 179–186 (2018).
  Medline CASGoogle Scholar
• 77. Alvanegh AG, Ganji SM, Kamel A et al. Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer. Biomed. Pharmacother. 140, 111755 (2021).
  Medline CASGoogle Scholar
• 78. Liu H, Bahreyni A, Mohamud Y, Xue YC, Jia WWG, Luo H. Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3. Mol. Ther. Oncolytics 27, 89–99 (2022).
  Medline CASGoogle Scholar
• 79. Sagara M, Takishima Y, Miyamoto S, Shimizu H, Nakanishi Y, Tani K. Novel recombinant coxsackievirus B3 infection elicits robust oncolytic activity against human non-small lung cancer and triple-negative breast cancer. J. Mol. Ther. 24, S162 (2016).
  Google Scholar
• 80. Cai L, Liu Z. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer. Cancer Med. 9(14), 5210–5220 (2020).
  Medline CASGoogle Scholar
• 81. Sagara M, Inoue H, Kuroda M et al. Coxsackievirus A11 induces robust oncolytic activity against human non-small cell lung cancer cells with immunostimulatory properties. Mol. Ther. 23, S171–S172 (2015).
  MedlineGoogle Scholar
• 82. Sakamoto A, Inoue H, Miyamoto S, Ito S, Soda Y, Tani K. Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer. Sci. Rep. 13(1), 5924 (2023).
  Medline CASGoogle Scholar
• 83. Rudin CM, Pandha HS, Zibelman M et al. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J. Immunother. Cancer 11(1), e005007 (2023).
  MedlineGoogle Scholar
• 84. Crimi S, Fiorillo L, Bianchi A et al. Herpes virus, oral clinical signs and QoL: systematic review of recent data. Viruses 11(5), 463 (2019).
  Medline CASGoogle Scholar
• 85. Kellish P, Shabashvili D, Rahman MM et al. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J. Clin. Invest. 129(6), 2279–2292 (2019).
  MedlineGoogle Scholar
• 86. Park KH, Kim G, Jang SH et al. Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Res. 23(2B), 1559–1564 (2003).
  Medline CASGoogle Scholar
• 87. Nagamachi Y, Tani M, Shimizu K, Yoshida T, Yokota J. Suicidal gene therapy for pleural metastasis of lung cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Cancer Gene Ther. 6(6), 546–553 (1999).
  Medline CASGoogle Scholar
• 88. Chiu CC, Kang YL, Yang TH, Huang CH, Fang K. Ectopic expression of herpes simplex virus-thymidine kinase gene in human non-small cell lung cancer cells conferred caspase-activated apoptosis sensitized by ganciclovir. Int. J. Cancer 102(4), 328–333 (2002).
  Medline CASGoogle Scholar
• 89. Fukunaga M, Takamori S, Hayashi A, Shirouzu K, Kosai K. Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann. Thorac. Surg. 73(6), 1740–1746 (2002).
  MedlineGoogle Scholar
• 90. Zhou JF, Chen G, Lu YP, Wang SX, Ma D. Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene transfer followed by ganiciclovir administration effectively inhibits growth of human small-cell lung cancer in a murine xenotransplant model. Zhonghua Zhong Liu Za Zhi. 26(2), 68–70 (2004).
  Medline CASGoogle Scholar
• 91. Van Dillen IJ, Mulder NH, Sluiter WJ et al. Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model. Anticancer Res. 25(1A), 255–261 (2005).
  Medline CASGoogle Scholar
• 92. Oh JY, Park MY, Kim DR et al. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase. Int. J. Mol. Med. 25(3), 369–376 (2010).
  Medline CASGoogle Scholar
• 93. Kim G, Park KH, Seol JY et al. Combination gene therapy of herpes simplex virus thymidine kinase and cytokines in lung cancer. Tuberc. Respir. Dis. 51(2), 135–146 (2016).
  Google Scholar
• 94. Osaki T, Tanio Y, Tachibana I et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54(20), 5258–5261 (1994).
  Medline CASGoogle Scholar
• 95. Chiu CC, Li CH, Fuh TS et al. The suppressed proliferation and premature senescence by ganciclovir in p53-mutated human non-small-lung cancer cells acquiring herpes simplex virus-thymidine kinase cDNA. Cancer Detect. Prev. 29(3), 286–293 (2005).
  Medline CASGoogle Scholar
• 96. Ji JS, Weng QY, Zhang F et al. Non-small-cell lung cancer: feasibility of intratumoral radiofrequency hyperthermia-enhanced herpes simplex virus thymidine kinase gene therapy. Radiology 288(2), 612–620 (2018).
  MedlineGoogle Scholar
• 97. Yang CT, Lin YC, Lin CL et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res. 25(3B), 2049–2054 (2005).
  Medline CASGoogle Scholar
• 98. Kanai R, Eguchi K, Takahashi M et al. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer – expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. J. Gene Med. 8(11), 1329–1340 (2006).
  Medline CASGoogle Scholar
• 99. Goodwin JM, Schmitt AD, McGinn CM et al. Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model. Cancer Invest. 30(3), 243–250 (2012).
  Medline CASGoogle Scholar
• 100. Lanuti M, Goodwin JM, Tanabe KK. Combined oncolysis and anti-angiogenesis gene therapy using a herpes simplex virus expressing endostatin in a murine lung cancer model. Mol. Ther. 13, S252–S253 (2006).
  Google Scholar
• 101. Adusumilli PS, Stiles BM, Chan MK et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann. Thorac. Surg. 80(2), 409–416 (2005).
  MedlineGoogle Scholar
• 102. Zhu B, Yang JR, Jiang YQ, Chen SF, Fu XP. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic embrane glycoprotein. Cell Biochem. Biophys. 69(3), 583–587 (2014).
  Medline CASGoogle Scholar
• 103. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10(18), 3013–3029 (1999).
  Medline CASGoogle Scholar
• 104. Sakata Y, Ino Y, Todo T, Ikeda N. Combination therapy of oncolytic herpes simplex virus type 1 with erlotinib in a human lung cancer xenograft model. J. Thorac. Oncol. 12(1), S1279 (2017).
  Google Scholar
• 105. Li JM, Kao KC, Li LF et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol. J. 10, 241 (2013).
  MedlineGoogle Scholar
• 106. Abolfathi H, Sheikhpour M, Mohammad Soltani B, Fahimi H. The comparison and evaluation of the miR-16, miR-155 and miR-146a expression pattern in the blood of TB and NSCLC patients: a research paper. Gene Rep. 22, 100967 (2021).
  CASGoogle Scholar
• 107. Wang X, Liu S, Zhou Z, Yan H, Xiao J. A herpes simplex virus type 2-encoded microRNA promotes tumor cell metastasis by targeting suppressor of cytokine signaling 2 in lung cancer. Tumour Biol. 39(5), 1010428317701633 (2017).
  Google Scholar
• 108. Kaur B, Chiocca EA. Personalizing oncolytic virotherapy? Mol. Ther. 15(1), 6–7 (2007).
  Medline CASGoogle Scholar
• 109. Bhattacharjee S, Yadava PK. Measles virus: background and oncolytic virotherapy. Biochem. Biophys. Rep. 13, 58–62 (2018).
  MedlineGoogle Scholar
• 110. Fujiyuki T, Yoneda M, Amagai Y et al. A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells. Oncotarget 6(28), 24895–24903 (2015).
  MedlineGoogle Scholar
• 111. Patel MR, Jacobson BA, Belgum H et al. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. J. Thorac. Oncol. 9(8), 1101–1110 (2014).
  Medline CASGoogle Scholar
• 112. Inoue H, Yasunari K, Sakamoto A et al. Genetically engineered measles virus Edmonston strain expressing the wild-type N, P, L genes (MV-NPL) is a promising oncolytic virotherapy agent against lung cancer stem cells. Mol. Ther. 20, S95 (2012).
  Google Scholar
• 113. Peikert T. Personalized oncolytic therapy: the next step toward the successful clinical application of vaccine-strain measles viruses for cancer therapy? J. Thorac. Oncol. 15(5), 689–691 (2020). •• Personalized medicine is one of the newest and most effective treatment approaches.
  MedlineGoogle Scholar
• 114. Obaid RF, Al-Khafaji YA, Obied HN, Al-Jibouri SA, Mohammed SJ, Al-Kilabi RF. Correlation between live attenuated measles viral load and growth inhibition percentage in non-small cell lung cancer cell line. J. Contemp. Med. Sci. 4(1), 45–50 ( 2018).
  CASGoogle Scholar
• 115. Zhao DH, Chen P, Yang HQ et al. Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer. Oncol. Rep. 29(1), 199–204 (2013).
  Medline CASGoogle Scholar
• 116. Xia M, Gonzalez P, Li CY et al. Oncolytic attenuated measles virus exploits autophagy for its replication and spreads by suppressing Rig-1 like receptors (RLRs) in non-small cell lung cancer cells. Cancer Res. 72, 2259 (2012).
  Google Scholar
• 117. Xia M, Meng G, Jiang A et al. Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus. Oncotarget 5(11), 3907–3918 (2014).
  MedlineGoogle Scholar
• 118. Chai Z, Zhang PY, Fu F et al. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virol. J. 11, 84 (2014).
  MedlineGoogle Scholar
• 119. Yan Y, Liang B, Zhang J, Liu Y, Bu X. Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro. Mol. Med. Rep. 11(1), 317–326 (2015).
  Medline CASGoogle Scholar
• 120. Li Q, Wei D, Feng F et al. α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus. J. Cancer Res. Clin. Oncol. 143(11), 2171–2181 (2017).
  Medline CASGoogle Scholar
• 121. Bian J, Wang K, Kong X et al. Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. Arch. Virol. 156(8), 1335–1344 (2011).
  Medline CASGoogle Scholar
• 122. Fu F, Zhao M, Yang YJ et al. Antiproliferative effect of Newcastle disease virus strain D90 on human lung cancer cell line A549. Oncol. Res. 19(7), 323–333 (2011).
  MedlineGoogle Scholar
• 123. Ye T, Jiang K, Wei L et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am. J. Cancer Res. 8(8), 1514–1527 (2018).
  Medline CASGoogle Scholar
• 124. Hua Y, Tao X, Guo X, Wang H, Liang W. Effect and safety of the Newcastle disease virus combined with chemotherapy for patients with advanced non-small cell lung cancer. Chin. J. Clin. Oncol. 39(13), 919–922 (2012).
  Google Scholar
• 125. Yurchenko KS, Zhou P, Kovner AV, Zavjalov EL, Shestopalova LV, Shestopalov AM. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLOS ONE 13(4), e0195425 (2018).
  MedlineGoogle Scholar
• 126. Jiang K, Li YC, Zhu QM et al. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. BMC Cancer 14, 551 (2014).
  MedlineGoogle Scholar
• 127. Hu LL, Sun SL, Wang TP et al. Oncolytic Newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. Am. J. Cancer Res. 5(12), 3612–3623 (2015).
  Medline CASGoogle Scholar
• 128. Yaacov B, Elihaoo E, Lazar I et al. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 15(12), 795–807 (2008).
  Medline CASGoogle Scholar
• 129. Song DZ, Fan XH, Huang C et al. Inhibitory effect of Newcastle disease virus on the growth of human small cell lung cancer xenografts. Tumor 29(6), 544–549 (2009).
  CASGoogle Scholar
• 130. Liang Y, Tian WY, Huang JJ, Gao LX, Fan XH. MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells. Oncol. Lett. 21(6), 482 (2021).
  Medline CASGoogle Scholar
• 131. Chan WM, McFadden G. Oncolytic poxviruses. Annu. Rev. Virol. 1(1), 191–141 (2014).
  Google Scholar
• 132. Chaurasiya S, Chen NG, Lu J et al. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models. Cancer Gene Ther. 27(3–4), 125–135 (2020).
  Medline CASGoogle Scholar
• 133. Hu JQ, Wang HY, Gu JF, Liu XY, Zhou XM. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. Acta Biochim. Biophys. Sin. 50(10), 1018–1027 (2018).
  CASGoogle Scholar
• 134. Rintoul JL, Lemay CG, Tai LH et al. ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol. Ther. 20(6), 1148–1157 (2012).
  Medline CASGoogle Scholar
• 135. Christie JD, Appel N, Canter H et al. Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma. Mol. Ther. Oncolytics 22, 539–554 (2021).
  Medline CASGoogle Scholar
• 136. Hofmann E, Weibel S, Szalay AA. Combination treatment with oncolytic vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J. Transl. Med. 12(1), 197 (2014).
  MedlineGoogle Scholar
• 137. Weibel S, Hofmann E, Basse-Luesebrink TC et al. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J. Transl. Med. 11, 106 (2013).
  MedlineGoogle Scholar
• 138. Chintala NK, Choe JK, McGee E et al. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma. Front. Immunol. 14, 1112960 (2023).
  Medline CASGoogle Scholar
• 139. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol. Ther. 22(1), 102–111 (2014).
  Medline CASGoogle Scholar
• 140. Ekeke CN, Russell KL, Murthy P et al. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. J. Thorac. Cardiovasc. Surg. 163(4), e313–e328 (2022).
  MedlineGoogle Scholar
• 141. Lv CW, Su QS, Liang YP, Hu JL, Yuan SJ. Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. Biochem. Biophys. Res. Commun. 476(1), 21–28 (2016).
  Medline CASGoogle Scholar
• 142. Remy-Ziller C, Thioudellet C, Hortelano J et al. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model. Hum. Vaccin. Immunother. 14(1), 140–145 (2018).
  MedlineGoogle Scholar
• 143. Sun F, Guo ZS, Gregory AD, Shapiro SD, Xiao GT, Qu ZX. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J. Immunother. Cancer 8(1), e000294 (2020).
  MedlineGoogle Scholar
• 144. Tenesaca S, Vasquez M, Alvarez M et al. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. J. Immunother. Cancer 9(7), e001587 (2021).
  MedlineGoogle Scholar
• 145. Shi Z, Liu B, Huang C et al. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Biochem. Biophys. Res. Commun. 559, 176–182 (2021).
  Medline CASGoogle Scholar
• 146. Liu GH, Wang WL, Wang C et al. Livin modulates the apoptotic effects of vesicular stomatotitis virus in lung adenocarcinoma. Int. J. Oncol. 47(5), 1775–1782 (2015).
  Medline CASGoogle Scholar
• 147. Malilas W, Koh SS, Lee S et al. Suppression of autophagic genes sensitizes CUG2-overexpressing A549 human lung cancer cells to oncolytic vesicular stomatitis virus-induced apoptosis. Int. J. Oncol. 44(4), 1177–1184 (2014).
  Medline CASGoogle Scholar
• 148. Patel KMR, Dash A, Jacobson BA et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther. 26(11–12), 411–418 (2019).
  Medline CASGoogle Scholar
• 149. Patel MR, Jacobson BA, Ji Y et al. Vesicular stomatitis virus expressing interferon-beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget 6(32), 33165–33177 (2015).
  MedlineGoogle Scholar
• 150. Schreiber L, Urbiola C, Spiesschaert B et al. Oncolysis dominated therapeutic effect of LCMV-GP–pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model. Eur. J. Cancer 110, S15–S16 (2019).
  Google Scholar
• 151. Patel MR, Jacobson BA, Ji Y, Hebbel RP, Kratzke RA. Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing interferon-β in preclinical models of non-small cell lung cancer. Transl. Oncol. 13(7), 100782 (2020).
  MedlineGoogle Scholar
• 152. Sei S, Mussio JK, Yang QE et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol. Cancer 8, 47 (2009).
  MedlineGoogle Scholar
• 153. Villalona-Calero MA, Lam E, Otterson GA et al. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer 122(6), 875–883 (2016).
  Medline CASGoogle Scholar
• 154. Maatta AM, Makinen K, Ketola A et al. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int. J. Cancer 123(7), 1704–1711 (2008).
  Medline CASGoogle Scholar
• 155. Määttä A-M, Wahlfors T, Häkkinen K et al. Evaluation of lung cancer virotherapy with oncolytic semliki forest virus using immunodeficient rodent tumor model. Mol. Ther. 13, S17 (2006).
  Google Scholar
• 156. Masemann D, Köther K, Kuhlencord M et al. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. Oncoimmunology 7(5), e1423171 (2018).
  MedlineGoogle Scholar
• 157. Masemann D, Meissner R, Schied T et al. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune-checkpoint inhibitors against IC-resistant lung cancers. Oncoimmunology 10(1), 1885778 (2021).
  MedlineGoogle Scholar
• 158. Strauss J, Madan R, Bilusic M et al. Oncolytic parainfluenza virus 5 vector enhances natural killer cell killing of lung tumor cells in 2D and 3D spheroid cultures. J. Immunother. 8(3), A1–A559 (2020).
  Google Scholar
• 159. Varudkar N, Oyer JL, Copik A, Parks GD. Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type i and type III interferon signaling. J. Immunother. Cancer 9(6), e002373 (2021).
  MedlineGoogle Scholar
• 160. Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J. Natl Cancer Inst. 105(14), 1059–1065 (2013).
  Medline CASGoogle Scholar
• 161. Liu F, Wang Q, Huang Y, Wang N, Shan H. Rescue of NanoLuc luciferase-expressing senecavirus A with oncolytic activity. Virus Res. 292, 198232 (2021).
  Medline CASGoogle Scholar
• 162. Vacchelli E, Eggermont A, Fridman CS et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2(6), e24612 (2013).
  MedlineGoogle Scholar
• 163. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther. 16(6), 473–488 (2009).
  Medline CASGoogle Scholar
• 164. Li Z, Feiyue Z, Gaofeng L, Haifeng L. Lung cancer and oncolytic virotherapy – enemy’s enemy. Transl. Oncol. 27, 101563 (2023).
  Medline CASGoogle Scholar
• 165. Rosewell Shaw A, Suzuki M. Recent advances in oncolytic adenovirus therapies for cancer. Curr. Opin. Virol. 21, 9–15 (2016).
  MedlineGoogle Scholar
• 166. Toth K, Wold WSM. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2(9), 1844–1866 (2010).
  Medline CASGoogle Scholar
• 167. Niemann J, Kühnel F. Oncolytic viruses: adenoviruses. Virus Genes 53(5), 700–706 (2017).
  Medline CASGoogle Scholar